


Biden Administration Proposes $35 Billion Coverage for Anti-Obesity Drugs Amid Challenges from Incoming Trump Officials
The Biden administration's rule seeks to allow Medicare and Medicaid coverage for anti-obesity medications, but faces potential opposition and budget concerns.
Subscribe to unlock this story
We really don't like cutting you off, but you've reached your monthly limit. At just $5/month, subscriptions are how we keep this project going. Start your free 7-day trial today!
Get StartedHave an account? Sign in
Overview
On November 26, 2024, the Biden administration proposed a $35 billion plan to cover anti-obesity drugs like Wegovy and Zepbound under Medicare and Medicaid, potentially benefiting millions. However, the rule, requiring Congressional approval, faces skepticism from incoming Trump administration officials, particularly Robert F. Kennedy Jr., who opposes the drugs. While a bipartisan coalition supports the initiative, concerns regarding its high cost and the necessity of price negotiations with manufacturers persist among some lawmakers.
Report issue

Read both sides in 5 minutes each day
Analysis
Analysis unavailable for this viewpoint.
Articles (24)
Center (13)
History
- 10M4 articles
- 10M4 articles